TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03486730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT1718
Description: Dose escalation will consist of Stage 1 and 2. Stage 1 patients will receive BT1718 intravenously twice a week (D: 1,4,8,11,15,18) for 3 out of 4 weeks. Starting dose will be 0.6mg/m2. Single patient cohorts will be explored, but it will change to 3 to 6 patients cohorts. Stage 2 patients will receive BT1718 intravenously once a week (D: 1,8,15) for 3 out of 4 weeks. This stage will have 3 to 6 patient cohorts until the recommended dose is established. The expansion phase will consist of two or more expansion cohorts to include tumour types known to commonly over-express MT1-MMP and where MT1-MMP overexpression is confirmed during prospective and retrospective (in appropriate patients) selection at enrolment. A squamous NSCLC and basket cohort will include approximately 16 patients each with high MT1-MMP levels. In the expansion cohorts BT1718 will be administered intravenously at the once weekly RP2D established in Phase I, Stage 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT1718
Description: Dose escalation will consist of Stage 1 and 2. Stage 1 patients will receive BT1718 intravenously twice a week (D: 1,4,8,11,15,18) for 3 out of 4 weeks. Starting dose will be 0.6mg/m2. Single patient cohorts will be explored, but it will change to 3 to 6 patients cohorts. Stage 2 patients will receive BT1718 intravenously once a week (D: 1,8,15) for 3 out of 4 weeks. This stage will have 3 to 6 patient cohorts until the recommended dose is established. The expansion phase will consist of two or more expansion cohorts to include tumour types known to commonly over-express MT1-MMP and where MT1-MMP overexpression is confirmed during prospective and retrospective (in appropriate patients) selection at enrolment. A squamous NSCLC and basket cohort will include approximately 16 patients each with high MT1-MMP levels. In the expansion cohorts BT1718 will be administered intravenously at the once weekly RP2D established in Phase I, Stage 2.
Study: NCT04960358

Intervention type: PROCEDURE
Intervention: Surface Electromyography
Description: will be applied Surface Electromyography to assess Flexion Relaxation Response
Study: NCT03469011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Oral Tablet
Description: 3+3 trial design. Cohorts of 3-6 patients with escalating imatinib doses. No intra-patient dose escalation allowed.
Study: NCT03731130

Intervention type: OTHER
Intervention: EORTC QLQ CR29
Description: standardized questionaire
Study: NCT03084419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: The IV dose varies according to weight:~\<60kg=500mg~≥60 but≤100kg=750mg \>100kg=1g~This equates to approximately 10mg/kg.
Study: NCT04002271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Target controlled infusion (TCI) with modified Marsh effect site model (Fresenius Kabi) will be used for induction and maintenance of general anaesthesia. Level of anaesthesia will be titrated to produce a BIS value of between 40-60. For induction, remifentanil 1mcg/kg and rocuronium 0.6 mg/kg will be given intravenously prior to intubation. Sevoflurane will not be given. Air and oxygen will be given, and FiO2 will be kept at between 35-50%. Similarly, to the GAS group, remifentanil will be infused at a rate of between 0.1-0.2mcg/kg/min and titrated according to the haemodynamic parameters stated for the GAS group. Morphine sulphate will be given at a dose of 0.1mg/kg before skin incision. TCI propofol and remifentanil will be switched off at the end of the procedure. Reversal of muscle relaxation will be achieved as for the GAS group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Patients in the GAS group will be induced with intravenous bolus propofol 1.5-3mg/kg, remifentanil 1mcg/kg, and rocuronium 0.6mg/kg for induction of general anaesthesia and intubation of patient. General anesthesia monitoring will be used. Maintenance of general anesthesia to be provided using sevoflurane, together with air and oxygen. FiO2 will be maintained between 35-50%. Bispectral (BIS) monitoring will be applied and level of anaesthesia will be maintained at a BIS value of 40-60. Remifentanil infusion will be given at between 0.1-0.2mcg/kg/min, to be titrated to maintain mean arterial blood pressure within 20% of baseline (blood pressure in ward before surgery as baseline) and heart rate between 45 to 100 bpm. Morphine sulphate to be given at a dose of 0.1mg/kg before skin incision. Sevoflurane and remifentanil infusion will be switched off at the end. Reversal of muscle relaxation to be achieved using intravenous neostigmine 50mcg/kg and atropine 20mcg/kg after the operation.
Study: NCT03395522

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTind
Description: device implanted for 5-7 days
Study: NCT01013727

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SPECT : ECD-Tc99m - Neurolite, Bristol-Myers Squibb Medical Imaging

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SPECT : ECD-Tc99m - Neurolite, Bristol-Myers Squibb Medical Imaging
Study: NCT03884075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide injection once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide injection once weekly
Study: NCT01870466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: cilostazol bid for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: cilostazol bid for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: cilostazol bid for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: cilostazol bid for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: cilostazol bid for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: cilostazol bid for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: simvastatin qd for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: simvastatin qd for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: simvastatin qd for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: simvastatin qd for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: rosuvastatin qd for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: rosuvastatin qd for 7 days
Study: NCT02288637

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olyset Plus LLIN
Description: Olyset Plus is a LLIN containing the pyrethroid permethrin and the synergist piperonyl butoxide PBO as the active ingredients (AI).The LLIN can withstand repeated washing and retains efficacy over years of use

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olyset Plus LLIN
Description: Olyset Plus is a LLIN containing the pyrethroid permethrin and the synergist piperonyl butoxide PBO as the active ingredients (AI).The LLIN can withstand repeated washing and retains efficacy over years of use

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Olyset LLIN
Description: Olyset Plus is a LLIN containing the pyrethroid permethrin. The LLIN can withstand repeated washing and retains efficacy over years of use.
Study: NCT04002271

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anaesthesia
Description: Patients in the SA group will receive intrathecal (L4-5, or L3-4 if failed at L4-5) administration of 2.2-2.4ml 0.5% heavy bupivicaine using a 25G Whitacare needle. No intrathecal opioid will be given during the procedure. Light sedation will be given during surgery with target-controlled infusion of propofol using the Marsh effect site model (0.3 -1 mcg/ml). Supplemental oxygen 2L/min will be given via the nasal cannula.
Study: NCT02288637

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Olyset LLIN
Description: Olyset Plus is a LLIN containing the pyrethroid permethrin. The LLIN can withstand repeated washing and retains efficacy over years of use.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Olyset LLIN
Description: Olyset Plus is a LLIN containing the pyrethroid permethrin. The LLIN can withstand repeated washing and retains efficacy over years of use.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IRS
Description: Actellic CS (Syngenta), is a microcapsule formulation of the organophosphate insecticide, pirimiphos-methyl. Microencapsulation greatly extends the compound's residual life when applied to interior walls and ceilings. Evaluation by LSHTM in experimental huts in Tanzania showed residual activity of more than a year. Parallel trials in Benin against pyrethroid-resistant mosquitoes killed more than 80% of An. gambiae for up to 10 months.
Study: NCT04033289

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hip protection orthosis
Description: Experimental group would wear hip protection orthosis over 12 hours a day for 1 year.
Study: NCT01747902

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biceps Tenotomy
Description: The biceps tenotomy group will have their bicep treated by detaching the tendon from the shoulder.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biceps Tenodesis
Description: The biceps tenodesis group will have their bicep detached and then re-inserted onto the shoulder.
Study: NCT01320254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin, Gemcitabine, Panitumumab
Description: Cisplatin 25mq/sq.m. at day 1+8 and Gemcitabine 1000mg/sq.m. at day 1 + 8 Panitumumab 9mg/kg BW at day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin, Gemcitabine
Description: Cisplatin 25mq/sq.m. at day 1+8 and Gemcitabine 1000mg/sq.m. at day 1 + 8
Study: NCT01039207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rilotumumab
Description: Given IV
Study: NCT02153827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric Shoulder External Rotator Training
Description: Eccentric training exercise for the external rotators, 3 sets of 15 daily.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: General Shoulder exercise
Description: general exercise consisting of active shoulder movements
Study: NCT00748930

Intervention type: OTHER
Intervention: Retrospective Chart Review and Data collection
Description: Retrospective Chart Review and Data collection
Study: NCT03873688

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: expiratory muscle training
Description: The intensity of training will been determined after assessment of maximal expiratory pressure (MEP). The first training session will perform under the supervision of a physiotherapist, patients will perform training at home. MEP measurement will reevaluate every two weeks and the intensity of training will set according to MEP levels.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: expiratory muscle training
Description: The intensity of training will been determined after assessment of maximal expiratory pressure (MEP). The first training session will perform under the supervision of a physiotherapist, patients will perform training at home. MEP measurement will reevaluate every two weeks and the intensity of training will set according to MEP levels.
Study: NCT00299221

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: tacrolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: tacrolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combination therapy
Description: MMF
Study: NCT03637829

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White chocolate
Description: Experimental snack treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dark chocolate 1
Description: Experimental snack treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dark chocolate 2
Description: Experimental snack treatment
Study: NCT02944266

Intervention type: OTHER
Intervention: Pre operative Focus assessed Transthoracic echocardiographic assessment.

Intervention type: OTHER
Intervention: Pre operative Focus assessed Transthoracic echocardiographic assessment.
Study: NCT03091335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music-listening
Description: Patients listen to music on headphones
Study: NCT01972490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avastin
Description: Drug: avastin On day 1 of a 14 day treatment cycle, patients received a 2-hour infusion of avastin (5mg/kg) followed by chemotherapy of mFOLFOX6 until progressive disease or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: mFOLFOX-6 (oxaliplatin, 85mg/m2 on day 1 infused during 2 hours;LV400mg/m2 on days 1 infused during 2 hours, followed by FU 400 mg/m2 intravenous bolus then 2400 mg/m2 continuous infusion for 46 hours)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6
Description: mFOLFOX-6 (oxaliplatin, 85mg/m2 on day 1 infused during 2 hours;LV400mg/m2 on days 1 infused during 2 hours, followed by FU 400 mg/m2 intravenous bolus then 2400 mg/m2 continuous infusion for 46 hours)
Study: NCT02753179

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head Impulse Tests
Description: Head Impulse Tests are performed by the clinician who holds the patient's head in his hands, while he is looking straight at an earth-fixed target; then by turning the patient's head abruptly and unpredictably to the left or right, up or down through a small angle (only 10-20 degrees - not a large angle). 20 impulses in each directions (6) will be performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic visual acuity Test (DVAT)
Description: Dynamic visual acuity Test (DVAT) assesses visual acuity during head movement relative to baseline static visual acuity. DVA will be assessed actively during self-generated rotations of the head in different directions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VEMPs & VEMPo
Description: VEMPs \& VEMPo are sound evoked muscular contractions of the neck or eye. They are recorded using an evoked response computer, a sound generator, and surface electrodes to pick up neck or eye muscle activation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dizziness Handicap Inventory
Description: Dizziness Handicap Inventory is a questionnaire that identify difficulties that patient may be experiencing because of dizziness, yielding to a score ranging from 0 to 100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oscillopsia severity questionnaire
Description: Oscillopsia severity questionnaire is a 9 items questionnaires that identify oscillopsia in different circumstances.
Study: NCT01966484

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Succinylcholine
Description: Anaesthesia was induced and maintained with propofol(1-2mg/kg and 5mg/kg/h) and remifentanil (1µg/kg and 0,2µ/kg/min). The study arm is immobilized and a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. the patients receive the muscle relaxant according to the study group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mivacurium
Description: Anaesthesia was induced and maintained with propofol(1-2mg/kg and 5mg/kg/h) and remifentanil (1µg/kg and 0,2µ/kg/min). The study arm is immobilized and a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. the patients receive the muscle relaxant according to the study group.
Study: NCT02846363

Intervention type: OTHER
Intervention: public awareness campaign
Description: The public awareness campaign was based on improving knowledge and skills of public to recognize stroke symptoms. The campaign materials were:~* 3 posters presenting the three main symptoms of stroke and the need to call the EMS immediately~* A leaflet on stroke will be created~* 3 participatory movies: These films will be posted on YouTube and broadcast on the website and the Facebook campaign page~* Actions on social networks: A Facebook group will be created (AVC: votre appel peut sauver des vie).~* A website developed with ICAP - UCBL Lyon1 (http://avc.univ-lyon1.fr/)~* On the occasion of World Stroke Day, held annually on 29 October, will be organized an event in Lyon in order to educate and inform the general public about stroke: the main symptoms and reflexes to adopt in case of stroke: call the EMS urgently
Study: NCT04322292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-CAR088
Description: Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10\^6 anti-BCMA CAR+T cells/kg.~Divided into three dose ranges of low(1.0-3.0×10\^6 CAR+T cells/kg),medium(3.0-6.0×10\^6 CAR+T cells/kg) and high(6.0-9.0×10\^6 CAR+T cells/kg).~Other Name: CBM.BCMA Chimeric Antigen Receptor T cell.
Study: NCT04222413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metarrestin
Description: Phase IA: Loading dose on Day 1 of Cycle 1 for Dose Levels 1-7. Loading dose on Days 1 and 3 of Cycle 1 for Dose Levels 8-11. After the loading dose on Day 1 or Days 1 and 3 of Cycle 1, continue on Mondays-Wednesdays-Fridays of every following cycle. Phase IB: PO according to the dose and schedule estimated during Phase IA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metarrestin
Description: Phase IA: Loading dose on Day 1 of Cycle 1 for Dose Levels 1-7. Loading dose on Days 1 and 3 of Cycle 1 for Dose Levels 8-11. After the loading dose on Day 1 or Days 1 and 3 of Cycle 1, continue on Mondays-Wednesdays-Fridays of every following cycle. Phase IB: PO according to the dose and schedule estimated during Phase IA
Study: NCT02278835

Intervention type: OTHER
Group type: OTHER
Intervention: breathing exercises
Description: 3 sets of 10 repetitions of deep breathing exercises

Intervention type: DEVICE
Group type: OTHER
Intervention: incentive spirometry
Description: 3 sets of 10 repetitions of deep breathing exercises with incentive spirometry

Intervention type: DEVICE
Group type: OTHER
Intervention: Intermittent positive pressure breathing
Description: 20 minutes breathing with intermittent positive pressure

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous positive airway pressure
Description: 20 minutes breathing with continuous positive airway pressure
Study: NCT03397251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMDS
Description: The device will be implanted during an already planned surgical intervention for aortic dissection repair. The participant will be observed and data gathered during the surgery and routine standard of care follow up visits.
Study: NCT04244097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: after induction of general anesthesia and before the start of surgery, after inflating the pneumoperitoneum and before any surgical manipulation, the surgeon infuse 50 mL of blinded solution (bupivacaine or bupivacaine neostigmine) intraperitoneally to the sub-diaphragmatic space and gall bladder area guided by the camera and the patients are kept in Trendelenburg position for 5-10 minutes. Thereafter all patients will be positioned in the anti-Trendelenburg position to start the surgery and the laparoscopic procedure will be carried out in a standard fashion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: after induction of general anesthesia and before the start of surgery, after inflating the pneumoperitoneum and before any surgical manipulation, the surgeon infuse 50 mL of blinded solution (bupivacaine or bupivacaine neostigmine) intraperitoneally to the sub-diaphragmatic space and gall bladder area guided by the camera and the patients are kept in Trendelenburg position for 5-10 minutes. Thereafter all patients will be positioned in the anti-Trendelenburg position to start the surgery and the laparoscopic procedure will be carried out in a standard fashion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: after induction of general anesthesia and before the start of surgery, after inflating the pneumoperitoneum and before any surgical manipulation, the surgeon infuse 50 mL of blinded solution (bupivacaine or bupivacaine neostigmine) intraperitoneally to the sub-diaphragmatic space and gall bladder area guided by the camera and the patients are kept in Trendelenburg position for 5-10 minutes. Thereafter all patients will be positioned in the anti-Trendelenburg position to start the surgery and the laparoscopic procedure will be carried out in a standard fashion.
Study: NCT03548363

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gingest powdered extract obtained from Ginger rhizomes
Description: Description: Powdered extract obtained from Ginger rhizomes. Botanical name: Zingiber officinale Roscoe Plant part used: Dried rhyzome Extraction solvent: CO2 Extract Ratio 45-60 / 1 100mg of extract are equivalent to an average of 4400 mg of dry ginger rhizomes~Composition: Natural extract, Calcium Hydroxide, Polysorbate 80, De-oiled soya lecithin, Calcium silicate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gingest powdered extract obtained from Ginger rhizomes
Description: Description: Powdered extract obtained from Ginger rhizomes. Botanical name: Zingiber officinale Roscoe Plant part used: Dried rhyzome Extraction solvent: CO2 Extract Ratio 45-60 / 1 100mg of extract are equivalent to an average of 4400 mg of dry ginger rhizomes~Composition: Natural extract, Calcium Hydroxide, Polysorbate 80, De-oiled soya lecithin, Calcium silicate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200 mg/d maltodextrin
Study: NCT01851135

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological examination and quality of life measures

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological examination and quality of life measures